vs
Side-by-side financial comparison of NATIONAL RESEARCH CORP (NRC) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
NATIONAL RESEARCH CORP is the larger business by last-quarter revenue ($35.2M vs $23.0M, roughly 1.5× Intellia Therapeutics, Inc.). NATIONAL RESEARCH CORP runs the higher net margin — 5.1% vs -416.2%, a 421.3% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -4.6%). NATIONAL RESEARCH CORP produced more free cash flow last quarter ($6.1M vs $-69.4M). Over the past eight quarters, NATIONAL RESEARCH CORP's revenue compounded faster (-0.2% CAGR vs -10.8%).
National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
NRC vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $23.0M |
| Net Profit | $1.8M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 13.3% | -428.9% |
| Net Margin | 5.1% | -416.2% |
| Revenue YoY | -4.6% | 78.8% |
| Net Profit YoY | -72.6% | 25.7% |
| EPS (diluted) | $49.58 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $23.0M | ||
| Q3 25 | $34.6M | $13.8M | ||
| Q2 25 | $34.0M | $14.2M | ||
| Q1 25 | $33.6M | $16.6M | ||
| Q4 24 | $36.9M | $12.9M | ||
| Q3 24 | $35.8M | $9.1M | ||
| Q2 24 | $35.0M | $7.0M | ||
| Q1 24 | $35.3M | $28.9M |
| Q4 25 | $1.8M | $-95.8M | ||
| Q3 25 | $4.1M | $-101.3M | ||
| Q2 25 | $-106.0K | $-101.3M | ||
| Q1 25 | $5.8M | $-114.3M | ||
| Q4 24 | $6.6M | $-128.9M | ||
| Q3 24 | $5.7M | $-135.7M | ||
| Q2 24 | $6.2M | $-147.0M | ||
| Q1 24 | $6.4M | $-107.4M |
| Q4 25 | 13.3% | -428.9% | ||
| Q3 25 | 22.4% | -808.9% | ||
| Q2 25 | 4.7% | -772.2% | ||
| Q1 25 | 25.6% | -726.6% | ||
| Q4 24 | 26.0% | -1059.9% | ||
| Q3 24 | 22.3% | -1589.0% | ||
| Q2 24 | 25.3% | -1998.6% | ||
| Q1 24 | 24.8% | -394.0% |
| Q4 25 | 5.1% | -416.2% | ||
| Q3 25 | 11.9% | -735.2% | ||
| Q2 25 | -0.3% | -710.8% | ||
| Q1 25 | 17.2% | -687.6% | ||
| Q4 24 | 17.8% | -1001.2% | ||
| Q3 24 | 15.9% | -1489.5% | ||
| Q2 24 | 17.6% | -2112.6% | ||
| Q1 24 | 18.0% | -371.3% |
| Q4 25 | $49.58 | $-0.81 | ||
| Q3 25 | $0.18 | $-0.92 | ||
| Q2 25 | $-0.01 | $-0.98 | ||
| Q1 25 | $0.25 | $-1.10 | ||
| Q4 24 | $0.27 | $-1.27 | ||
| Q3 24 | $0.24 | $-1.34 | ||
| Q2 24 | $0.26 | $-1.52 | ||
| Q1 24 | $0.27 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.0M | $671.4M |
| Total Assets | $134.9M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | $449.9M | ||
| Q3 25 | $2.2M | $511.0M | ||
| Q2 25 | $5.3M | $459.7M | ||
| Q1 25 | $2.5M | $503.7M | ||
| Q4 24 | $4.2M | $601.5M | ||
| Q3 24 | $3.5M | $658.1M | ||
| Q2 24 | $485.0K | $691.1M | ||
| Q1 24 | $1.7M | $791.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $48.7M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $35.2M | — |
| Q4 25 | $14.0M | $671.4M | ||
| Q3 25 | $14.3M | $748.4M | ||
| Q2 25 | $21.3M | $715.3M | ||
| Q1 25 | $29.7M | $779.9M | ||
| Q4 24 | $31.3M | $872.0M | ||
| Q3 24 | $34.6M | $962.6M | ||
| Q2 24 | $40.2M | $971.1M | ||
| Q1 24 | $36.9M | $1.0B |
| Q4 25 | $134.9M | $842.1M | ||
| Q3 25 | $135.7M | $925.3M | ||
| Q2 25 | $141.4M | $898.9M | ||
| Q1 25 | $135.2M | $986.2M | ||
| Q4 24 | $132.5M | $1.2B | ||
| Q3 24 | $131.8M | $1.2B | ||
| Q2 24 | $119.1M | $1.2B | ||
| Q1 24 | $120.9M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $7.2M | $-69.3M |
| Free Cash FlowOCF − Capex | $6.1M | $-69.4M |
| FCF MarginFCF / Revenue | 17.2% | -301.6% |
| Capex IntensityCapex / Revenue | 3.2% | 0.5% |
| Cash ConversionOCF / Net Profit | 3.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | $15.7M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.2M | $-69.3M | ||
| Q3 25 | $13.8M | $-76.9M | ||
| Q2 25 | $-1.1M | $-99.6M | ||
| Q1 25 | $6.6M | $-148.9M | ||
| Q4 24 | $6.4M | $-85.2M | ||
| Q3 24 | $9.4M | $-84.8M | ||
| Q2 24 | $6.8M | $-58.2M | ||
| Q1 24 | $12.0M | $-120.7M |
| Q4 25 | $6.1M | $-69.4M | ||
| Q3 25 | $10.2M | $-76.9M | ||
| Q2 25 | $-4.1M | $-99.9M | ||
| Q1 25 | $3.7M | $-149.7M | ||
| Q4 24 | $1.9M | $-86.2M | ||
| Q3 24 | $7.8M | $-86.1M | ||
| Q2 24 | $1.5M | $-59.2M | ||
| Q1 24 | $7.9M | $-123.2M |
| Q4 25 | 17.2% | -301.6% | ||
| Q3 25 | 29.4% | -558.2% | ||
| Q2 25 | -12.2% | -701.0% | ||
| Q1 25 | 10.9% | -900.1% | ||
| Q4 24 | 5.2% | -669.4% | ||
| Q3 24 | 21.8% | -945.2% | ||
| Q2 24 | 4.3% | -850.9% | ||
| Q1 24 | 22.4% | -425.7% |
| Q4 25 | 3.2% | 0.5% | ||
| Q3 25 | 10.4% | 0.2% | ||
| Q2 25 | 8.8% | 1.7% | ||
| Q1 25 | 8.9% | 4.4% | ||
| Q4 24 | 12.0% | 7.6% | ||
| Q3 24 | 4.5% | 14.0% | ||
| Q2 24 | 15.0% | 14.5% | ||
| Q1 24 | 11.7% | 8.7% |
| Q4 25 | 3.99× | — | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NRC
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
